SCHEMBL20530664

SCHEMBL20530664

COC(=O)c1cccc(-c2c(CN(C(=O)OC)C3c4ccccc4-c4ccccc43)cccc2C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 1/20 0.42
NR1H2 P55055 3/20 0.41
NR1H3 Q13133 1/20 0.41
PDK2 Q15119 1/20 0.41
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 2/20 0.39
CYP2D6 P10635 1/20 0.39
SCN5A Q14524 1/20 0.38
SCN9A Q15858 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
EPHX2 P34913 1/20 0.36
SDHB P21912 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
P4HB P07237 1/20 0.36
KIF11 P52732 1/20 0.35
NOTUM Q6P988 1/20 0.35
DGAT2 Q96PD7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28330790 0.78 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3CYP2D6NR1H4
SCHEMBL3064761 0.77 LOXL2 (0.49) RAB9AMRGPRX4
SCHEMBL20530666 0.77 RBP4 (0.41) RBP4NR1H2NR1H3PDK2SCN5A
SCHEMBL7823276 0.73 PDK2 (0.57) RBP4NR1H2PDK2SCN9ANPC1
SCHEMBL20530668 0.72 SLC6A3 (0.41) PDK2SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL6629911 0.67 MRGPRX4 (0.50) RBP4NR1H2NR1H3PDK2NR1H4
SCHEMBL3343465 0.66 NOTUM (0.50) RBP4PDK2SCN9ANOTUM
SCHEMBL25186501 0.65 PPARG (0.41) RBP4SLC6A2SLC6A4SLC6A3EPHX2
SCHEMBL1760520 0.65 GPR3 (0.40) SLC6A2SLC6A4SLC6A3CYP2D6EPHX2
SCHEMBL27549930 0.64 GPR3 (0.42) SLC6A2SLC6A4SLC6A3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3609905-B1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2022-06-08 EP disclosed
US-11091514-B2 Peptide macrocycles and use thereof in the treatment of bacterial infections HOFFMANN-LA ROCHE INC. (US) 2021-08-17 US disclosed
EP-3609905-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS H. Hoffnabb-La Roche Ag (CH) 2020-02-19 EP disclosed
US-20200040032-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 2020-02-06 US disclosed
WO-2018189063-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2018-10-18 WO disclosed
EP-3388445-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2018-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091514-B2 Peptide macrocycles and use thereof in the treatment of bacterial infections VIP, NPY5R, CXCR3 RBP4 1141/4885NR1H2 214/4885NR1H3 193/4885
US-20200040032-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS VIP, NPY5R, CXCR3 RBP4 1141/4885NR1H2 214/4885NR1H3 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.